PPA
LOGC

Parametric Portfolio Associates’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Parametric Portfolio Associates’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14,563
Closed -$111K – 4098
2020
Q4 		$111K Buy
+14,563
New +$97.4K ﹤0.01% 3875

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Parametric Portfolio Associates's LOGC Position: Q1 2021 in Review

Parametric Portfolio Associates sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q1 2021, closing a stake of 14,563 shares — an estimated $111K sold.

Parametric Portfolio Associates first reported a position in LOGC in Q4 2020 and held it in 1 quarter. The position peaked at $111K in Q4 2020. 61 funds tracked by Wall St. Rank hold LOGC as of Q1 2021.

  • Parametric Portfolio Associates reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Parametric Portfolio Associates sold 14,563 LogicBio Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $111K.
  • Parametric Portfolio Associates first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Parametric Portfolio Associates's LogicBio Therapeutics, Inc. Common Stock position peaked at $111K in Q4 2020.
  • 61 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Parametric Portfolio Associates's 13F filing for Q1 2021, filed 17 May 2021.